Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Medicinas Complementares
Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Neurocrit Care ; 38(1): 41-51, 2023 02.
Artigo em Inglês | MEDLINE | ID: mdl-36071331

RESUMO

BACKGROUND: The objective of this study was to determine the prevalence of pyridoxine deficiency, measured by pyridoxal phosphate (PLP) levels, in patients admitted to the hospital with established (benzodiazepine-resistant) status epilepticus (SE) (eSE) and to compare to three control groups: intensive care unit (ICU) patients without SE (ICU-noSE), non-ICU inpatients without SE (non-ICU), and outpatients with or without a history of epilepsy (outpatient). METHODS: This retrospective cohort study was conducted at the University of North Carolina Hospitals and Yale New Haven Hospital. Participants included inpatients and outpatients who had serum PLP levels measured during clinical care between January 2018 and March 2021. The first PLP level obtained was categorized as normal (> 30 nmol/L), marginal (≤ 30 nmol/L), deficient (≤ 20 nmol/L), and severely deficient (≤ 5 nmol/L). RESULTS: A total of 293 patients were included (52 eSE, 40 ICU-noSE, 44 non-ICU, and 157 outpatient). The median age was 55 (range 19-99) years. The median PLP level of the eSE group (12 nmol/L) was lower than that of the ICU-noSE (22 nmol/L, p = 0.003), non-ICU (16 nmol/L, p = 0.05), and outpatient groups (36 nmol/L, p < 0.001). Patients with eSE had a significantly higher prevalence of marginal and deficient PLP levels (90 and 80%, respectively) than patients in each of the other three groups (ICU-noSE: 70, 50%; non-ICU: 63, 54%; outpatient: 38, 21%). This significantly higher prevalence persisted after correcting for critical illness severity and timing of PLP level collection. CONCLUSIONS: Our study confirms previous findings indicating a high prevalence of pyridoxine deficiency (as measured by serum PLP levels) in patients with eSE, including when using a more restricted definition of pyridoxine deficiency. Prevalence is higher in patients with eSE than in patients in all three control groups (ICU-noSE, non-ICU, and outpatient). Considering the role of pyridoxine, thus PLP, in the synthesis of γ-aminobutyric acid and its easy and safe administration, prospective studies on pyridoxine supplementation in patients with eSE are needed.


Assuntos
Estado Epiléptico , Deficiência de Vitamina B 6 , Humanos , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Piridoxal , Piridoxina , Fosfato de Piridoxal , Deficiência de Vitamina B 6/epidemiologia , Estudos Prospectivos , Estudos Retrospectivos , Estado Epiléptico/tratamento farmacológico , Estado Epiléptico/epidemiologia
2.
Clin J Oncol Nurs ; 26(3): 313-317, 2022 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-35604734

RESUMO

Electrolyte imbalances can frequently occur among patients with cancer. Hypomagnesemia and hypokalemia are side effects of certain chemotherapies, including cisplatin, cetuximab, eribulin, and ifosfamide. When patients concurrently receive chemotherapy and take medications that cause hypomagnesemia or hypokalemia, electrolyte imbalances are amplified. Provider and patient education are vital to identifying and treating these conditions in a timely manner. If medication usage depletes electrolytes, repletion through diet and supplements is essential. In symptomatic cases of electrolyte deficiency, oral and IV formulations of potassium and magnesium are options for treatment. This article discusses the importance of identifying and understanding the etiologies, symptoms, and treatment modalities of hypomagnesemia and hypokalemia.


Assuntos
Hipopotassemia , Neoplasias , Cisplatino/uso terapêutico , Eletrólitos/uso terapêutico , Humanos , Hipopotassemia/induzido quimicamente , Hipopotassemia/tratamento farmacológico , Magnésio/uso terapêutico , Neoplasias/complicações , Neoplasias/tratamento farmacológico , Potássio/uso terapêutico
3.
J Microbiol ; 58(6): 489-498, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32329017

RESUMO

The growing threat of emergent multidrug-resistant enteric bacterial pathogens, and their adopted virulence properties are directing to find alternative antimicrobials and/or development of dietaries that can improve host gut health and/or defense. Recently, we found that modified Lactobacillus casei (Lc + CLA) with increased production of conjugated linoleic acid has antimicrobial and other beneficial properties. Further, prebiotic alike products such as berry pomace extracts (BPEs), increase the growth of probiotics and inhibit the growth of certain bacterial pathogens. In this study, we evaluated the antibacterial effect of genetically modified Lc + CLA along with BPEs against major enteric pathogen Salmonella enterica serovar Typhimurium (ST). In mixed culture condition, the growth of ST was significantly reduced in the presence of Lc + CLA and/or BPEs. Bacterial cell-free cultural supernatant (CFCS) collected from wild-type Lc or modified Lc + CLA strains also inhibited the growth and survival of ST, and those inhibitory effects were enhanced in the presence of BPEs. We also found that the interaction of the pathogen with cultured host (HD-11 and INT-407) cells were also altered in the presence of either Lc or Lc + CLA strain or their CFCSs significantly. Furthermore, the relative expression of genes related to ST virulence and physicochemical properties of ST was altered by the effect of CFCSs of either Lc or Lc + CLA. These findings indicate that a diet containing synbiotic, specifically linoleic acid, over-produced Lc + CLA and prebiotic product BPEs, might have the potential to be effective in controlling ST growth and pathogenesis.


Assuntos
Antibacterianos/farmacologia , Lacticaseibacillus casei/metabolismo , Ácido Linoleico/farmacologia , Extratos Vegetais/farmacologia , Prebióticos/microbiologia , Probióticos/farmacologia , Salmonella typhimurium/efeitos dos fármacos , Animais , Linhagem Celular , Frutas/química , Humanos , Salmonella typhimurium/patogenicidade , Virulência/efeitos dos fármacos
4.
Pediatr Neurol ; 81: 31-37, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29526345

RESUMO

BACKGROUND: This study aims to improve the rate of folic acid supplementation to adolescent women with epilepsy on an antiepileptic drug (AED) regimen seen by the pediatric neurology providers at the Children's Hospital at Montefiore, in compliance with the 2009 American Academy of Neurology and American Epilepsy Society practice parameter. METHODS: We designed a quality improvement study with implementation of a series of interventions and compared folic acid supplementation rates before and after intervention. We made additional comparisons based on specific age groups (12 to 15 years and 16 to 21 years) and a diagnosis with or without developmental impairment. RESULTS: A review of 1850 charts from 2004 to 2015 showed an average folic acid prescription rate of 41%. Supplementation rates gradually increased to 52.2%, 58.5%, 60.3%, and finally up to 81.6% after this respective intervention: initial email reminder, provider education, posting signs in examination rooms, and implementation of an electronic medical record best practice advisory. There was improvement across all categories, in both age groups (12 to 15 years and 16 to 21 years) and in those with or without developmental impairment. There was a trend for higher compliance rates in adolescents without developmental impairment. CONCLUSIONS: Our interventions resulted in an increase in folic acid supplementation rates of adolescent women with epilepsy. These results are encouraging. We plan to extend education about the recommendations for folic acid supplementation to non-neurology providers, as well as expand to apply our interventions and assess adherence to other defined epilepsy quality measures.


Assuntos
Anticonvulsivantes/uso terapêutico , Anormalidades Congênitas/prevenção & controle , Prescrições de Medicamentos/estatística & dados numéricos , Epilepsia/tratamento farmacológico , Ácido Fólico/administração & dosagem , Adesão à Medicação/estatística & dados numéricos , Complexo Vitamínico B/administração & dosagem , Adolescente , Adulto , Anticonvulsivantes/efeitos adversos , Criança , Estudos de Coortes , Registros Eletrônicos de Saúde/estatística & dados numéricos , Feminino , Humanos , Malformações do Sistema Nervoso/prevenção & controle , Cidade de Nova Iorque , Adulto Jovem
5.
J Am Osteopath Assoc ; 117(12): e137-e140, 2017 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-29181524

RESUMO

The diagnosis and management of parotitis can be challenging. Patients often present with pain and edema in the neck, jaw, head, and ear due to congestion of the gland. Parotitis is typically caused by an infection within the parotid gland and surrounding lymph nodes, and the infection can spread to nearby cervical fascial planes and cause major complications if not managed successfully. Specific guidelines for the outpatient management of parotitis are limited, and outpatient treatment failures are common, requiring inpatient therapy with multiple broad-spectrum antibiotics. In the current case, a comprehensive patient-centered approach was used to treat a woman whose overlapping clinical conditions, lifestyle, and work factors led to an infection of the parotid gland.


Assuntos
Antibacterianos/uso terapêutico , Osteopatia , Parotidite/diagnóstico , Antibacterianos/efeitos adversos , Feminino , Humanos , Levofloxacino/efeitos adversos , Levofloxacino/uso terapêutico , Pessoa de Meia-Idade , Parotidite/tratamento farmacológico , Parotidite/terapia , Tomografia Computadorizada por Raios X , Xerostomia/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA